The gutting of DNDN's pipeline due to halting all work on everything but the Provenge BLA, no early-stage PCa trials on the horizon for Provenge, and two financings at $4.50 are perfect examples of why management teams should partner their first drugs even if the deals are not perfect.
At this point, let's all cross our fingers and hope the advisory panel is feeling patient-focused and reasonable that day.
News 
Market Data 
Discover 
